502 related articles for article (PubMed ID: 20490653)
1. Should bisphosphonates be utilized in the adjuvant setting for breast cancer?
Lipton A
Breast Cancer Res Treat; 2010 Aug; 122(3):627-36. PubMed ID: 20490653
[TBL] [Abstract][Full Text] [Related]
2. Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant benefit?
Gnant M; Dubsky P; Fitzal F; Blaha P; Schoppmann S; Steger G; Marth C; Samonigg H; Hüttner K; Fohler H; Ruecklinger E; Jakesz R; Greil R;
Clin Breast Cancer; 2009 Jun; 9 Suppl 1():S18-27. PubMed ID: 19561003
[TBL] [Abstract][Full Text] [Related]
3. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
Brufsky A
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
[TBL] [Abstract][Full Text] [Related]
4. Zoledronic acid for adjuvant use in patients with breast cancer.
Ressler S; Mlineritsch B; Greil R
Expert Rev Anticancer Ther; 2011 Mar; 11(3):333-49. PubMed ID: 21417849
[TBL] [Abstract][Full Text] [Related]
5. Intravenous bisphosphonates for breast cancer: impact on patient outcomes and scientific concepts.
Gnant M
Breast Dis; 2011; 33(2):71-81. PubMed ID: 22142663
[TBL] [Abstract][Full Text] [Related]
6. Current and future status of adjuvant therapy for breast cancer.
Coleman RE
Cancer; 2003 Feb; 97(3 Suppl):880-6. PubMed ID: 12548590
[TBL] [Abstract][Full Text] [Related]
7. New results from the use of bisphosphonates in cancer patients.
Coleman R; Gnant M
Curr Opin Support Palliat Care; 2009 Sep; 3(3):213-8. PubMed ID: 19561507
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonates: ready for use as adjuvant therapy of breast cancer?
Theriault RL
Curr Opin Obstet Gynecol; 2010 Feb; 22(1):61-6. PubMed ID: 19934757
[TBL] [Abstract][Full Text] [Related]
9. The role of bisphosphonates in early breast cancer.
Paterson AH
Oncologist; 2006; 11 Suppl 1():13-9. PubMed ID: 16971735
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonates and breast cancer incidence and recurrence.
Chlebowski RT; Col N
Breast Dis; 2011; 33(2):93-101. PubMed ID: 22142660
[TBL] [Abstract][Full Text] [Related]
11. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
Gnant MF; Mlineritsch B; Luschin-Ebengreuth G; Grampp S; Kaessmann H; Schmid M; Menzel C; Piswanger-Soelkner JC; Galid A; Mittlboeck M; Hausmaninger H; Jakesz R;
J Clin Oncol; 2007 Mar; 25(7):820-8. PubMed ID: 17159195
[TBL] [Abstract][Full Text] [Related]
12. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
[TBL] [Abstract][Full Text] [Related]
15. Bisphosphonates in breast cancer: antitumor effects.
Aft R
Clin Adv Hematol Oncol; 2011 Apr; 9(4):292-9. PubMed ID: 21558988
[TBL] [Abstract][Full Text] [Related]
16. Zoledronic acid: multiplicity of use across the cancer continuum.
Lipton A
Expert Rev Anticancer Ther; 2011 Jul; 11(7):999-1012. PubMed ID: 21806323
[TBL] [Abstract][Full Text] [Related]
17. The evolving role of bone-conserving therapy in patients with breast cancer.
Brufsky AM
Semin Oncol; 2010 Jun; 37 Suppl 1():S12-9. PubMed ID: 20682367
[TBL] [Abstract][Full Text] [Related]
18. Moving into the future: treatment of bone metastases and beyond.
Hortobagyi GN
Cancer Treat Rev; 2005; 31 Suppl 3():9-18. PubMed ID: 16249057
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant bisphosphonates: a new standard of care?
Gnant M
Curr Opin Oncol; 2012 Nov; 24(6):635-42. PubMed ID: 23042123
[TBL] [Abstract][Full Text] [Related]
20. The role of antiresorptive therapies in improving patient care in early and metastatic breast cancer.
Candelaria-Quintana D; Dayao ZR; Royce ME
Breast Cancer Res Treat; 2012 Apr; 132(2):355-63. PubMed ID: 21987034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
